Effects of intranasal 17&bgr;-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women

Objective: Oral estrogen increases the levels of C-reactive protein (CRP), which is an independent risk factor for coronary heart disease in healthy individuals. The aim of our study was to investigate the effects of intranasal 17&bgr;-estradiol (E2) on serum CRP and its most potent stimulant, interleukin-6 in healthy postmenopausal women. Design: Thirty-six healthy postmenopausal women (45-54 y) were enrolled. According to their individual preferences, they were assigned to intranasal (n = 10), transdermal (n = 14), or oral (n = 12) continuous E2 treatment with a sequential progestin (10-14 d in a 28-d cycle). Blood samples were drawn at baseline and after 3, 6, and 12 months during the estrogen-only phase to adjust for the progestin effect. Results: In women taking intranasal or transdermal E2, there were no significant changes in median serum CRP levels during the 12-month treatment period. In women taking oral E2 preparations, serum median CRP levels were significantly higher compared to baseline after 6 and 12 months of the therapy (P < 0.05). Conversely, serum median bioactive interleukin-6 levels were significantly lower after 6 and 12 months in women taking E2 intranasally or orally and after 12 months in women taking E2 transdermally (P < 0.05). Conclusions: The results of our study show that intranasal, similarly to transdermal, E2 administration does not increase serum CRP levels in postmenopausal women. They also support the hypothesis that CRP increase during oral estrogen treatment is not mediated by the enhancement of interleukin-6 production by the immune cells but is rather caused by the hepatic first-pass metabolism effect.

[1]  Candace S. Brown,et al.  Testosterone Patch for Low Sexual Desire in Surgically Menopausal Women: A Randomized Trial , 2005 .

[2]  M. Naruszewicz,et al.  Does the type of hormone replacement therapy affect lipoprotein (a), homocysteine, and C-reactive protein levels in postmenopausal women? , 2005, Metabolism: clinical and experimental.

[3]  K. Aittomäki,et al.  Levels of serum C-reactive protein during oral and transdermal estradiol in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. , 2005, The Journal of clinical endocrinology and metabolism.

[4]  J. Cline,et al.  Gonadal hormone substitutes: Effects on the cardiovascular system , 2005, Osteoporosis International.

[5]  P. Delmas,et al.  Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route. , 2004, Maturitas.

[6]  M. Altındiş,et al.  Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. , 2003, Maturitas.

[7]  T. Strandberg,et al.  Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women. , 2003, The American journal of cardiology.

[8]  G. Rosano,et al.  Increased Levels of C-Reactive Protein After Oral Hormone Replacement Therapy May Not Be Related to an Increased Inflammatory Response , 2003, Circulation.

[9]  I. Jialal,et al.  Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. , 2003, Journal of the American College of Cardiology.

[10]  E. Schaefer,et al.  Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women. , 2003, The American journal of cardiology.

[11]  C. Stehouwer,et al.  Effects of Transdermal and Oral Oestrogen Replacement Therapy on C-Reactive Protein Levels in Postmenopausal Women: A Randomised, Placebo-Controlled Trial , 2002, Thrombosis and Haemostasis.

[12]  M. Cazzaniga,et al.  Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women , 2002, Circulation.

[13]  J. Manson,et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. , 2002, JAMA.

[14]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[15]  J. Jespersen,et al.  Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations. , 2002, American journal of obstetrics and gynecology.

[16]  R. Cannon,et al.  Statin Attenuates Increase in C-Reactive Protein During Estrogen Replacement Therapy in Postmenopausal Women , 2002, Circulation.

[17]  A. Wakatsuki,et al.  Effect of Medroxyprogesterone Acetate on Vascular Inflammatory Markers in Postmenopausal Women Receiving Estrogen , 2002, Circulation.

[18]  D. Rachoń,et al.  Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women. , 2002, The Journal of endocrinology.

[19]  R. Tracy,et al.  Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. , 2001, The American journal of cardiology.

[20]  M. Taskinen,et al.  Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women , 2001, Thrombosis and Haemostasis.

[21]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[22]  S. Fichtlscherer,et al.  Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease , 2000, Circulation.

[23]  E. Giltay,et al.  Oral Ethinyl Estradiol, but not Transdermal 17β-estradiol, Increases Plasma C-reactive Protein Levels in Men , 2000, Thrombosis and Haemostasis.

[24]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[25]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[26]  H. Schunkert,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Hormone Replacement Therapy and Interrelation between Serum Interleukin-6 and Body Mass Index in Postmenopausal Women: A Population-Based Study , 2022 .

[27]  中込 明裕.  Interferon-γ and Lipopolysaccharide Potentiate Monocyte Tissue Factor Induction by C-Reactive Protein Relationship With Age, Sex, and Hormone Replacement treatment , 2000 .

[28]  R. Tracy,et al.  The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[30]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[31]  N. Sattar,et al.  Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes , 1999, The Lancet.

[32]  C. Stehouwer,et al.  Increased C-reactive Protein Levels during Short-term Hormone Replacement Therapy in Healthy Postmenopausal Women , 1999, Thrombosis and Haemostasis.

[33]  C. Christiansen,et al.  Efficacy and acceptability of intranasal 17 β-oestradiol for menopausal symptoms: randomised dose-response study , 1999, The Lancet.

[34]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  C. Christiansen,et al.  Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. , 1999, Lancet.

[36]  W. Koenig,et al.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[37]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[38]  E. Barrett-Connor,et al.  Hormone replacement therapy, heart disease, and other considerations. , 1998, Annual review of public health.

[39]  E. Barrett-Connor.  Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. , 1997, Circulation.

[40]  I. T. Ten Berge,et al.  CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. , 1996, Journal of immunology.

[41]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.

[42]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[43]  Irving Kushner,et al.  C‐reactive protein increases production of IL‐1α, IL‐1β, and TNF‐α, and expression of mRNA by human alveolar macrophages , 1993, Journal of Leukocyte Biology.

[44]  P. Heinrich,et al.  Acute‐phase response of human hepatocytes: Regulation of acute‐phase protein synthesis by interleukin‐6 , 1990, Hepatology.

[45]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[46]  B. Sherwin,et al.  The role of androgen in the maintenance of sexual functioning in oophorectomized women. , 1987, Psychosomatic medicine.

[47]  B. Sherwin,et al.  Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. , 1985, Psychosomatic medicine.

[48]  R. E. Ranney.  Comparative metabolism of 17alpha-ethynyl steroids used in oral contraceptives. , 1977, Journal of toxicology and environmental health.